BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38468469)

  • 1. SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway.
    Li X; Li G; Li L; Gao B; Niu X; Wang Y; Wang Z
    Brain Behav; 2024 Mar; 14(3):e3465. PubMed ID: 38468469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIM22 actives PI3K/Akt/mTOR pathway to promote psoriasis through enhancing cell proliferation and inflammation and inhibiting autophagy.
    Ren Y; Dong H; Jin R; Jiang J; Zhang X
    Cutan Ocul Toxicol; 2022 Dec; 41(4):304-309. PubMed ID: 36170453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
    Li L; Qi Y; Ma X; Xiong G; Wang L; Bao C
    Cell Biol Int; 2018 Sep; 42(9):1192-1199. PubMed ID: 29762880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of autophagy induced by activation of the AMPK/ERK/mTOR signaling pathway after TRIM22-mediated DENV-2 infection of HUVECs.
    Wu N; Gou X; Hu P; Chen Y; Ji J; Wang Y; Zuo L
    Virol J; 2022 Dec; 19(1):228. PubMed ID: 36587218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.
    Zhang J; Yang Y; Dong Y; Liu C
    Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34913078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of an immune infiltration/tumor proliferation-related Notch3 nomogram for predicting survival in patients with primary glioblastoma.
    Zheng ZQ; Zhang GG; Yuan GQ; Hao JH; Nie QQ; Zheng MC; Wang Z
    Front Genet; 2023; 14():1148126. PubMed ID: 37284062
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of TRIM22 by IFN-γ Involves JAK and PC-PLC/PKC, but Not MAPKs and pI3K/Akt/mTOR Pathways.
    Gao B; Xu W; Wang Y; Zhong L; Xiong S
    J Interferon Cytokine Res; 2013 Oct; 33(10):578-87. PubMed ID: 23659673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXC1‑mediated TRIM22 regulates the excessive proliferation and inflammation of fibroblast‑like synoviocytes in rheumatoid arthritis via NF‑κB signaling pathway.
    Wei Y; Huang X; Ma Y; Dai L
    Mol Med Rep; 2022 Oct; 26(4):. PubMed ID: 35946462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway.
    Li Y; Ma X; Wang Y; Li G
    Biomed Pharmacother; 2017 Sep; 93():435-443. PubMed ID: 28666210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinnamaldehyde Downregulation of Sept9 Inhibits Glioma Progression through Suppressing Hif-1
    Wang Z; Wang C; Fu J; Liu R; Zhou X
    Dis Markers; 2022; 2022():6530934. PubMed ID: 35096204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Fibronectin 1 on Cell Proliferation, Senescence and Apoptosis of Human Glioma Cells Through the PI3K/AKT Signaling Pathway.
    Liao YX; Zhang ZP; Zhao J; Liu JP
    Cell Physiol Biochem; 2018; 48(3):1382-1396. PubMed ID: 30048971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroglobin promotes the proliferation and suppresses the apoptosis of glioma cells by activating the PI3K/AKT pathway.
    Zhang B; Liu Y; Li Y; Zhe X; Zhang S; Zhang L
    Mol Med Rep; 2018 Feb; 17(2):2757-2763. PubMed ID: 29207186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis.
    Zhang L; Zhang B; Wei M; Xu Z; Kong W; Deng K; Xu X; Zhang L; Ζhao X; Yan L
    Int J Oncol; 2020 May; 56(5):1225-1239. PubMed ID: 32319602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα.
    Ji J; Ding K; Luo T; Zhang X; Chen A; Zhang D; Li G; Thorsen F; Huang B; Li X; Wang J
    Cell Death Differ; 2021 Jan; 28(1):367-381. PubMed ID: 32814880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RPA3 promotes the proliferation, migration, and invasion of gliomas by activating the PI3K-AKT-mTOR pathway.
    Liang L; Zhao Z; Jin Q; Zhang S; Zhao Z; Li X
    Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):80-86. PubMed ID: 37571896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.
    Liu W; Zhao Y; Wang G; Feng S; Ge X; Ye W; Wang Z; Zhu Y; Cai W; Bai J; Zhou X
    Redox Biol; 2022 Jul; 53():102344. PubMed ID: 35636015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway.
    Jiang L; Wang C; Lei F; Zhang L; Zhang X; Liu A; Wu G; Zhu J; Song L
    Oncotarget; 2015 Apr; 6(10):8286-99. PubMed ID: 25823655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
    Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
    Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM22 promotes the proliferation of glioblastoma cells by activating MAPK signaling and accelerating the degradation of Raf-1.
    Fei X; Dou YN; Sun K; Wei J; Guo Q; Wang L; Wu X; Lv W; Jiang X; Fei Z
    Exp Mol Med; 2023 Jun; 55(6):1203-1217. PubMed ID: 37258577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of TRIM37 suppresses the proliferation, migration and invasion of glioma cells through the inactivation of PI3K/Akt signaling pathway.
    Tang SL; Gao YL; Wen-Zhong H
    Biomed Pharmacother; 2018 Mar; 99():59-64. PubMed ID: 29324313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.